ClearPoint Neuro, Inc.

ClearPoint Neuro, Inc. held its Annual Meeting on May 20, 2026, where stockholders approved the Seventh Amended and Restated 2013 Incentive Compensation Plan, elected seven directors, ratified Cherry Bekaert LLP as the independent auditor for 2026, and provided advisory approval for executive compensation. Following the meeting, the Board appointed new committee memberships for the Audit, Compensation, and Corporate Governance and Nominating Committees. Additionally, R. John Fletcher was confirmed as the Chairman of the Board.

ClearPoint Neuro reported a 43% increase in total revenue to $12.1 million for the first quarter of 2026, primarily driven by a 66% rise in product revenue. Despite strong top-line growth, the company's net loss widened to $9.55 million, or $(0.32) per share, compared to a net loss of $6.03 million in the prior year. Cash and cash equivalents decreased to $35.59 million, with net cash used in operations increasing to $7.97 million. The company's acquisition of IRRAS in November 2025 expanded its neurocritical care portfolio, and management confirmed sufficient liquidity for the next twelve months.

ClearPoint Neuro, Inc. reported record first-quarter 2026 revenue of $12.1 million, a 43% increase year-over-year, driven by 25% organic growth in devices and the integration of IRRAflow. The company achieved a gross margin of 64% and made significant operational progress, including FDA clearance for its Velocity Alpha MR High Speed Surgical Drill System and Health Canada approval for its Neuro Navigation System. Despite these gains, the net loss widened to $9.552 million, and operating expenses increased by 44% due to the IRRAS acquisition. The company maintains its 2026 revenue guidance of $52.0 million to $56.0 million.